Abstract
Introduction

Erythropoietin (EPO) is a glycoprotein hormone that is mainly known as the principal regulator of erythropoiesis promoting survival, proliferation and differentiation of erythroid progenitor cells. The expression of EPO is induced by hypoxia-inducible transcription factors stimulated by decreased oxygen delivery as a result of anaemia or hypoxaemia
. Beyond this function, EPO reveals protective properties on other tissues because its receptor is expressed on a variety of other cells [3] .
Different pre-clinical models of ischaemic disease showed beneficial effects after EPO treatment through activation of EPO receptor-related pathways resulting in antiapoptotic effects and therefore strengthened cell survival [4] [5] [6] . In addition, EPO induces neovascularization in experimental models of ischaemic diseases [7] [8] [9] . This is related to increased mobilization of bone marrowderived cells (BMCs) , and subsequently migration into the ischaemic tissue [9, 10] .
Reduced apoptosis and enhanced neovascularization are the main effects of EPO treatment after myocardial infarction (MI).
These effects result in improved cardiac function associated with reduced size of infarction and increased vessel density [11] . [12] . 
Because the influence of EPO on BMCs may play a crucial role for these effects after MI, in this study
Materials and methods
Chimeric mouse model
Induction of MI
Ten weeks after transplantation, MI was induced as described previously [14] . 
Experimental protocol
Mice were divided into the following groups: (1) 
Cytokine serum levels
Serum levels of VEGF in saline treated and in EPO-treated mice were determined by ELISA following the protocol of the company (RayBiotech, Norcross, GA, USA).
Perfusion measurement by pinhole SPECT
Animals with EPO treatment as well as infarcted control animals (each n ϭ 6) were scanned. Imaging was performed 6 and 30 days after LAD-ligation as described previously [12] . [17] . Each polar map was adjusted for its own maximal value. The size of the defect was calculated with the use of a threshold of 60%, which was derived from the histological infarct sizes as described previously [12] . Defect (Fig. 1A) .
In (Fig. 1B) .
FACS analysis of EGFP
؉ cell populations in bone marrow (Fig. 2B) .
Effect on serum VEGF levels
To investigate the impact of EPO treatment on VEGF as a potential mediator of neovascularization, we performed an ELISA of saline treated and EPO-treated mice. Serum VEGF levels were significantly increased in EPO-treated mice compared to control (141.9 pg/ml versus 87.2 pg/ml; P Ͻ 0.05) (Fig. 3) . [12] . At day 6 after MI perfusion defects were similar in both groups. Evaluating change of defect size from day 6 (baseline) to day 30 after MI we found a relative reduction of perfusion defect sizes after EPO treatment (Ϫ3.44%, Fig. 4) , whereas an increase in perfusion defects (ϩ2.43%; Fig. 4E-G) was detected in control animals (P Ͻ 0.05).
Perfusion defects in EPO-treated mice
After showing enhanced homing of BMCs after EPO treatment, we evaluated the impact of EPO on cardiac perfusion after MI. We therefore used the SPECT technique which has recently been validated for non-invasive, repetitive and quantitative infarct size quantification in mice
Discussion
In this study, we focused on the effects of EPO treatment after MI on mobilization and homing of BMCs as well as the impact on myocardial perfusion. In this regard, we used a chimeric mouse model with BM expressing EGFP allowing a precise tracking of BMCs. Our main findings are the following: EPO treatment after MI results in (1) significant mobilization of BMCs into peripheral blood; (2) no depletion of bone marrow; (3) improved homing of BMCs into the infarcted myocardium; (4) improved BMC recruitment predominantly of CXCR-4
ϩ cells; (5) [9, 11, 23, 24] . Previous histological data showed an increase of vessel density in the infarct border zone [11] . This neovascularization was demonstrated to be related to migrated BMCs [9, 10] 
